·
·
Thursday, 17 September 2026dailybeirut.com
Tech & Science
Russia’s Gamaleya Center developed a vaccine effective against the Bundibugyo Ebola strain, now under clinical trials, as several African countries express interest despite no approved treatment yet existing for that strain.
The Russian Ministry of Foreign Affairs confirmed that multiple African countries have expressed interest in Russia’s experimental Ebola vaccine, which remains in clinical trial phases.
According to the ministry’s press office, as reported by the Russian newspaper Izvestia, “clinical trials of the Russian Ebola vaccine are still ongoing, yet our partners in African countries have already begun demonstrating interest in it.”
Russia emphasized its strong commitment to international efforts aimed at curbing the spread of Ebola virus disease caused by the Bundibugyo strain and affirmed active cooperation with the World Health Organization on this issue.
International concern has intensified over potential Ebola outbreaks across Africa, particularly involving the Bundibugyo strain—a variant known for its exceptional difficulty in containment due to the absence of any approved specific vaccine or targeted therapy.
In May, the Russian National Research Center for Epidemiology and Microbiology—known as the Gamaleya Center—announced that its previously developed Ebola vaccine provides protection against the Bundibugyo strain.
